Paladin Labs Inc. (CC:PLB) Expands Distribution Agreement with Shire Human Genetic Therapies HGT to Include ELAPRASE(TM) (Idursulfase)
8/9/2007 9:37:37 AM
MONTREAL, CANADA--(MARKET WIRE)--Aug 8, 2007 -- Paladin Labs Inc. (Toronto:PLB.TO - News), a leading Canadian specialty pharmaceutical company, today announced that it has expanded its current exclusive Canadian distribution agreement with Shire Human Genetic Therapies, Inc. (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ). Under the new agreement, Paladin will be distributing ELAPRASE(TM) (idursulfase) for Hunter syndrome in addition to REPLAGAL® (agalsidase alfa) for Fabry disease. Health Canada recently granted Shire HGT regulatory approval for ELAPRASE, indicated for enzyme replacement therapy in patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II).
comments powered by